A Multicenter, Open-label Phase II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Intratumoral Injection of Carbon Nanoparticle Iron Suspension (CNSI-Fe) in Combination With Radiotherapy in Patients With Solid Tumors
Latest Information Update: 01 Apr 2026
At a glance
- Drugs Ferrous-sulphate-Sichuan-Enray-Pharmaceutical-Sciences-Company (Primary)
- Indications Head and neck cancer; Soft tissue sarcoma; Solid tumours
- Focus Therapeutic Use
- Sponsors Sichuan Enray Pharmaceutical Sciences Company
Most Recent Events
- 01 Apr 2026 New trial record